Clinical Trial Update: Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma [NA]

View source ↗

Summary

This ClinicalTrials.gov entry evaluates a 37°C non-ionic contrast agent used during ERCP in patients with cholangitis and hilar cholangiocarcinoma; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Cholangitis

Drugs mentioned

• Non-ionic contrast agent

Snippet

Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province | Conditions: Cholangitis | NA | Status: NOT_YET_RECRUITING